Background: We evaluated the analytical performance of six different faecal calprotectin immunoassays together with their diagnostic accuracy in the discrimination between functional and organic bowel disorders. Methods: The faecal samples were obtained from inflammatory bowel disease patients (n = 27) at the time of diagnosis [Crohn's disease (n = 15), colitis ulcerosa (n = 12)], gastroenterologic disease control patients (n = 52) and rheumatologic disease control patients (n = 26). All individuals included in the study underwent a concurrent ileocolonoscopy. Analytical performance (imprecision, accuracy, carry-over, correlation and agreement) and diagnostic accuracy (sensitivity, specificity, likelihood ratios) of the different assays were evaluated. Results: All methods demonstrated good analytical performance, but within-run and total imprecision varied depending on the assay methodology used. Using Passing Bablok and Bland-Altman analyses, low quantitative agreement was observed between the assays. All assays showed excellent diagnostic accuracy, with areas under the receiver operating characteristic curves (ROC) ranging from 0.974 to 0.998. The AUCs were not significantly different between assays (p > 0.05). Diagnostic sensitivity at the
Introduction
Inflammatory bowel diseases (IBD) are chronic diseases that result from the inflammation of the intestinal wall and include Crohn's disease (CD) and ulcerative colitis (UC). In IBD, activated leukocytes infiltrate the mucosa and appear in faeces due to shedding in the intestinal lumen [1, 2] . According to the World Gastroenterology Organization, the diagnosis of IBD relies on a combination of physical examination, patient history as well as a number of diagnostic tests including laboratory analyses, stool examination, endoscopy, biopsy and imaging studies [3] .
Among the various (non-invasive) biomarkers that have been proposed over the past few years, faecal calprotectin has gained an important role [4, 5] . Calprotectin is a calcium binding protein present in the neutrophil cytoplasm, representing over 60% of cytosolic proteins. Consequently, faecal calprotectin concentration may be related to inflammation of the bowel mucosa in IBD. Despite some analytical and pre-analytical drawbacks [6] [7] [8] [9] [10] , encouraging data have recently been published about the clinical efficacy of this biomarker for monitoring disease activity, response to treatment and relapse [11, 12] . In addition, faecal calprotectin is resistant to bacterial degradation, being stable in stool for up to 3 days at room temperature, which adds more benefits to its use as a laboratory marker [13] .
Over the past years, different assays for the detection of faecal calprotectin have been introduced including point-of-care methods [7, [14] [15] [16] [17] [18] [19] [20] [21] . These methods have the advantage of being easy to use and allowing analysis as soon as the sample is received in the laboratory. In addition, results are rapidly available, which allows quick clinical decision making. However, as laboratories are being consolidated, more automated assays such as enzyme-linked immunoassays (ELISA) [7, 22, 23] , chemiluminescence immunoassays (CLIA), fluoro enzyme immunoassays (FEIA) and particle enhanced turbidimetric immunoassays (PETIA) for the measurement of faecal calprotectin have been introduced [10] .
The aim of this study was to evaluate six different automated faecal calprotectin immunoassays for the diagnosis of IBD using the results of ileocolonoscopy as the criterion standard. Analytical and diagnostic performances were compared for the different tests.
Materials and methods

Patient population
The total population consisted of 105 patients (median age, 35 years; range, 14-94 years; 44 males, 61 females) with suspicion of IBD for whom a stool sample for faecal calprotectin analysis was sent to the clinical laboratory. Of those 105 patients, 86 consecutive patients were recruited over a 6-month period at the OLV Hospital Aalst. Based on the endoscopic results (see further), these patients were categorised into 21 IBD patients, 39 gastroenterologic disease control patients (GCG) and 26 rheumatologic disease control patients (RCG). To enhance the diagnostic power of the likelihood calculations, 19 diagnostic stool samples from AZ Delta Roeselare were added from six IBD patients and 13 gastroenterologic disease control patients. A summary of the patient characteristics with the faecal calprotectin concentrations for the different assays is presented in Table 1 .
The main reasons for performing faecal calprotectin determination were diarrhoea, mucous or bloody stools, weight loss and abdominal pain and cramping. Diagnostic work-up included physical examination and case history, endoscopic and histologic analysis, radiologic work-up and laboratory tests. To allow accurate diagnosis, all included patients underwent ileocolonoscopy. Patients who had previously been diagnosed with IBD or had not received ileocolonoscopy were excluded. Other exclusion criteria included unclear diagnosis (e.g. indeterminate colitis), inability to collect enough faecal sample and age younger than 14 years. Senior gastroenterologists performed all endoscopies and findings were documented in a computer-based database. The final diagnosis of IBD (i.e. CD and UC) was independently made by a pathologist or gastroenterologist who was blinded for calprotectin results.
Faecal calprotectin was determined on a single stool sample in all patients. Samples were transported to the laboratory at room temperature and stored at - 20 °C prior to extraction. For all assays, all analyses were performed within the same freeze-thaw cycle of the faeces sample, except for the Inova assay, for which the samples underwent one additional freeze-thaw cycle [17] .
The study was performed with full respect for individuals' rights to confidentiality and in accordance with procedures supervised by Local Authorities responsible for Ethical Research (Belgian registration number of ethical approval B126201526847).
Measurement of faecal calprotectin
Faecal calprotectin extraction: To prevent pre-analytical variation [6, 10] , all samples were weighted and extracted with the Smart Prep Extraction Device (Roche Diagnostics, Mannheim, Germany) in accordance with the manufacturer's instructions but using the different company specific faecal calprotectin buffers. Extractions were performed in different batches, immediately followed by calprotectin analyses.
Faecal calprotectin tests: Measurement of faecal calprotectin was performed using six automated immunoassays: Thermo Fisher EliA Calprotectin 2 assay on the Phadia 250 (Thermo Fisher Scientific, Uppsala, Sweden); Diasorin Calprotectin assay on the Liaison (Diasorin S.P.A., Saluggia, Italy), Inova QUANTA Flash Calprotectin (research use only) on the Inova BIO-FLASH instrument (Inova Diagnostics, San Diego, CA, USA); Bühlmann fCAL Turbo (Bühlmann Laboratories AG, Schönenbuch, Switzerland) on the Roche Cobas c501 (Roche Diagnostics, Mannheim, Germany), Euroimmun Calprotectin assay (Euroimmun; Lübeck, Germany), on an automated ELISA instrument (QUANTA-Lyser 2; Inova) and Orgentec Calprotectin assay on the Alegria (Orgentec Diagnostika, Mainz, Germany). All assays were performed following manufacturer's instructions. An overview of the different methods is presented in Table 2 .
Comparison of immunoassays
Analytical performance: The imprecision was assessed by duplicate testing of at least five aliquots of extracted patient sample and internal quality control samples (one sample with a high calprotectin value and one with a low calprotectin value), according to the CLSI EP5-A2 guideline [24] . To determine the amount of carry-over, a sample with a high calprotectin concentration and one with a low concentration (i.e. blank extraction buffer) were analysed in the sequence HHBBB, where H is the sample with the high concentration and B is the blank [25] . Accuracy was evaluated from eQC samples (n = 4, 2 positive, 2 negative) obtained from the INSTAND ® external quality control program for faecal makers. For analytical method comparison, Bland-Altman plots, Passing-Bablok regression analysis and Pearson correlation coefficients were determined for all assays.
Diagnostic performance: Based on the results of the consecutive sample collection, receiver operating characteristics (ROC) analyses were carried out to determine the diagnostic performance of each test. Deduced from the results of the ROC-analyses, cutoff values with the highest sensitivity and specificity have been calculated for diagnosing IBD. In addition, using the results of the whole patient sample population (n = 105), the calculation of positive likelihood ratio's (LR) for IBD was performed for four result intervals for each assay ( < upper limit of normal (ULN), 1-3 × ULN, 3-10 × ULN and > 10 × ULN). Comparisons were made Table 2 FEIA, fluoro-enzyme immunoassay; CLIA, chemiluminescence immunoassay; PETIA, particle enhanced turbidimetric immunoassay; ELISA, enzyme-linked immunosorbent assay; LOQ, limit of quantification; NA, not applicable; NR, not reported.
using non-parametric tests (Kruskall-Wallis for unpaired samples). A p-value < 0.05 was considered statistically significant. All statistical analyses were performed using MEDCALC ® (software version 15.6.1, Ostend, Belgium).
Results
Analytical performance Imprecision, carry-over and accuracy
Within-run imprecision varied between 0.6% and 19.7%. Total imprecision results ranged from 1.5% to 23.3% (Table 3 ). The lowest imprecision was obtained with the CLIA methods and the highest with the ELISA assays. No significant carry-over was detected (< 0.03% for all methods). The results of the eQC-samples were qualitatively correctly interpreted (i.e. positive or negative) by all the assays using the manufacturer's cut-offs (Table 2) . However, important differences in the numerical values were obtained with the different assays.
Method comparison
The range of the faecal calprotectin concentrations and median faecal calprotectin concentrations in diagnostic IBD samples varied substantially between the measurement methods (Table 1) . Quantitative data distribution showed that calprotectin concentrations in diagnostic samples of IBD patients measured with the Diasorin method were significantly lower (p < 0.05) compared to the concentrations obtained with the Euroimmun, Orgentec and Phadia assays. The highest values were measured with the Orgentec assay, which were found significantly higher (p < 0.05) compared to the other assays (Figure 1) .
For the total population (i.e. disease + disease control group), significantly lower (p < 0.05) concentrations were obtained with the Diasorin assay compared to the Euroimmun, fCAL Turbo, Orgentec and Phadia assay. The Orgentec assay measured significantly higher (p < 0.05) compared to the Diasorin and Inova assay. For the other assays, no significant differences in faecal calprotectin concentration were found.
Using Pearson correlation, we assessed linear agreement among the different assays. The correlation coefficients (r) for all possible correlations are presented in Table 4 . The lowest correlation coefficients were observed between the Euroimmun assay and the Inova, Orgentec, fCAL Turbo and Diasorin assays (ranging from 0.60 to 0.75). For all other assays, we observed a very good correlation (mean r, 0.89; median, 0.90; range, 0.81-0.95) ( Table 4) . A high correlation does not mean that two methods have a good agreement. We therefore performed Passing-Bablok regression and BlandAltman analyses (Table 4) . These analyses showed low agreement between assays. Additionally, Bland-Altman analysis, which was performed by plotting the difference between observations against the mean, revealed that the difference between assays increased for increasing means (heteroscedasticity). The best agreement was observed between the results obtained with the Inova and Diasorin methods. Low and high kit-controls ranged from 20 to 60 μg/g and 130-270 μg/g. Kitcontrols for the EliA and Inova Quanta Flash assays were analysed 10 times in duplo, for the Diasorin, fCAL Turbo and Euroimmun assays, five in duplo determinations were performed. c Low and high patient-sample controls ranged from 15 to 60 μg/g and 100 to 450 μg/g, respectively. The patient-sample controls were measured five times in duplo for all assays.
d As internal kit-controls are reported as positive/ negative, no data for intra-run and total imprecision for kit-controls are available for this assay.
Diagnostic performance of the faecal calprotectin assays
Among the study population, the prevalence of IBD was 25.7% (27/105). Sensitivities and specificities were calculated for each faecal calprotectin method ( Table 5) At the cut-off value proposed by the manufacturer (i.e. 50 μg/g for all assays), sensitivity for all assays was 100%, but the specificity was much lower (Table 5) . No significant differences in specificity were obtained between the assays, except for the Phadia and Inova assay (p < 0.05). Based on the ROC curve analysis, cut-offs at fixed specificity of 75% and 95% differed between the assays, ranging from 41.3 to 142.9 μg/g and 110.0 to 411.9 μg/g faecal calprotectin, respectively (Table 5 ). Sensitivities at these cut-off levels ranged from 95.2% to 100% and 84.2% to 100%, but no significant differences in sensitivity were obtained between the assays.
Calculation of likelihoods and associated LRs for chosen result intervals clearly illustrated that the LR increases significantly when the faecal calprotectin concentration was higher than the cut-off value (Table 6) . Consequently, diagnostic information is lost when results are interpreted as positive/negative only. Bayes theorem was used to calculate post-test probabilities as a function of pre-test probability.
By defining result intervals, IBD was ruled out in 51 (64.6%), 60 (75.9%), 48 (67.6%), 48 (60.8%), 45 (57.0%) and 45 (57.0%) of the non-IBD patients with the Phadia, Diasorin, Inova, Bühlmann, Euroimmun and Orgentec assay (< 50 μg/g), respectively. Furthermore, calprotectin values between 1 and 3 times and 3 and 10 times the ULN have no clinical usefulness and cannot be used to exclude or to confirm the diagnosis of IBD, except for the 3-10 times ULN for the Diasorin assay, where the diagnosis of IBD was confirmed in seven of the IBD patients (25.9%) [LR = 10.1 (95% CI 2.2-45.7)]. The diagnosis was confirmed in 19 (70.4%), 13 (48.1%), 14 (56.0%), 20 (74.1%), 21 (77.8%) and 26 (96.3%) of the IBD patients when using a cut-off of > 500 μg/g faecal calprotectin with the Phadia, Diasorin, Inova, Bühlmann, Euroimmun and Orgentec assays, respectively.
Discussion
In this study, we evaluated and compared six current available faecal calprotectin assays and investigated whether quantitative results of different assays were comparable.
Generally, all evaluated faecal calprotectin assays demonstrated good analytical performance. Withinrun and total imprecision were found to be higher for the ELISA/FEIA techniques (Euroimmun, Orgentec and The 95% confidence intervals are indicated in brackets.
Phadia) compared to the CLIA/PETIA assays (Diasorin, Inova and Bühlmann fCAL Turbo). It should be mentioned that the protocol for Euroimmun calprotectin ELISA was applied on Inova QUANTA-Lyser 2, which is a non-validated instrument for this method. This could contribute to the higher imprecision results found for this assay.
Qualitative correlations between the methods from the different manufacturers were found to be good, but quantitative agreement was poor, which means that the result of one method cannot be replaced by the result of another (Table 4) . Therefore, faecal calprotectin concentrations are not interchangeable. These results are in line with a study from the UK National External Quality Assessment Service that revealed up to 3.8-fold differences between methods from different manufacturers [6] . This suggests that, among other possible reasons, the antibodies used in the different assays are directed against different complexes of the faecal calprotectin protein. In addition, the methods evaluated use different antibodies (monoclonal vs. polyclonal) of different origins (recombinant vs. s. native) with different immunoassay techniques (ELISA vs. PETIA vs. CLIA vs. FEIA) ( Table 2 ). With the introduction of more assays, efforts to harmonise faecal calprotectin assays would be of particular interest [26] . Our study and other studies identify the need for both a standardised calprotectin reference material against which these assays can be calibrated, as well as an in-house clinical evaluation. By comparing faecal calprotectin concentrations with endoscopy and histology, the diagnostic accuracy of the assays can be verified and if necessary, be used Table 5 : Sensitivities and specificities of the faecal calprotectin test at the the cut-off with maximal sensitivity and specificity, the manufacturer's cut-off, and cut-off with fixed specificity of 75% and 95%. Only the consecutive population (n = 86 patients) were selected for ROC curve analysis. CI, confidence interval; SE, standard error. The values are presented as likelihood ratios with the 95% confidence interval (in parentheses); ULN, upper limit of normal; CI, confidence interval.
Method
to establish local cut-off values according to the intended use of the assay (i.e. diagnostic vs. disease monitoring).
Along with non-standardisation between the different faecal calprotectin assays, pre-analytical issues of faecal calprotectin analyses can contribute to the (often large) variation in faecal calprotectin concentrations between different assays [6, 7, 10, 26] . In this study, all faecal samples where appropriately homogenised and weighed before extraction. Extraction was performed using the same extraction device (i.e. the Roche Smart Prep Extraction device) for all assays. By using this device, we excluded variation in faecal calprotectin concentrations due to liquid or hard faecal samples, which can be found when using other extraction devices [6] . Moreover, by adding the appropriate amount of extraction buffer based on the weighed faecal sample, we are convinced that the initial dilution was correct. These pre-analytical confounders need to be taken into account when laboratories are planning to determine faecal calprotectin concentrations.
Overall, the diagnostic performance of the six evaluated faecal calprotectin assays was excellent, with only minor differences in sensitivity and specificity. The diagnostic accuracy at the cut-off with the highest sum of sensitivity and specificity was high and not statistically different between the assays evaluated, signifying that the diagnostic performance of the various assays was comparable. Cut-off values calculated from ROC analyses for detection of IBD were considerably higher for the Orgentec assay (477 μg/g) than for the other assays, compared to the recommended cut-offs by all manufacturers (all 50 μg/g faeces). The sensitivity as well as specificity of all assays was comparable when using the optimal cut-offs. On the contrary, we found that all assays had a sensitivity of 100% when the cut-off of the manufacturer was used (i.e. 50 μg/g) but specificity at this cut-off value differed between the assays (ranging from 58.4% to 78.5%). This, together with the fact that there is not yet a standardised method for faecal calprotectin measurement, indicates that recommended cut-off values would have to be determined depending on the clinical setting they are used in [10] .
There is a close relationship between spondylarthropathies (SpA) and IBD. Clinically, 5%-10% of all patients with ankylosing spondylitis have concurrent IBD. Even in the absence of relevant gastrointestinal symptoms, microscopic gut inflammation was observed in more than 40% of SpA patients [27] . The presence of (microscopic) gut inflammation appears relevant for prognosis and therapeutic decision making as SpA patients with a chronic type of gut inflammation have a less favourable disease course. Therefore, faecal calprotectin analysis is part of the clinical diagnostic work-up of SpA patients [28] . In our study, 26 consecutive rheumatologic patients (24.8%) were included. However, a recalculation of the diagnostic performance of the different assays for IBD by excluding this control group revealed no significant differences in optimal cut-off values and performance characteristics of the different tests (data not shown).
A drawback of the use of a single cut-off value is that this diagnostic information is lost when results are interpreted as positive/negative only. For example, a calprotectin result higher than 477 μg/g (Orgentec) does not mean the patient has IBD; neither does a result lower than 477 μg/g rules out the diagnosis of IBD, but the probability is different. To tackle this interpretative ambiguity, we defined result intervals and, thus, take full advantage of the quantitative test data. In addition, LRs allow us to integrate (through Bayesian calculations) a physician's judgment about pre-test probability of the disease in the patients' cohort under estimation. For all assays, we were able to define intervals with associated LRs that increase when the results deviate quantitatively more from normal. Our approach results in a clear gain of diagnostic power of individual laboratory tests as compared with classic dichotomous interpretation [29] .
Interpretation of laboratory results must be done in the clinical context and in function of the pre-test probability [29] . For example, in our study, we determined that in patients with diarrhoea, mucous or bloody stools, weight loss and abdominal pain and cramping, the pretest probability for IBD is 25.7%. The post-test probability for IBD in these patients will be 31.0%, 77.4%, 49.3%, 39.4%, 19.6% and 19.6% for patients with a faecal calprotectin concentration between 3 and 10 times the ULN for the Phadia, Diasorin, Inova, Bühlmann, Euroimmun and Orgentec assay, respectively. The post-test probability for patients with a faecal calprotectin concentration greater than 10-fold the ULN will be 94.9%, 99.4%, 93.1%, 95.1%, 99.6% and 86.8% for the Phadia, Diasorin, Inova, Bühlmann, Euroimmun and Orgentec assay, respectively. These findings suggest that patients with a high pre-test probability and levels of faecal calprotectin greater than 10-fold the cut-off value have a high probability for having IBD, aiding in clinical decision making. However, these findings depend on the clinical setting and the assay used for faecal calprotectin determination and therefore need to be confirmed in larger cohorts of patients.
The strength of our study lies in the fact that we included six different assays, of which the Inova QUANTA Flash ® and EliA Calprotectin 2 are evaluated for the first time. In addition, we defined two well-described disease control populations, thereby reflecting the real clinical use of this test. However, our study also has two important limitations. Compared to other studies, we included a relative low number of samples. Second, the sensitivity of all assays at their recommended cut-off is 100%, which is in contrast to other studies. Including more IBD patients of which at least some have faecal calprotectin concentrations lower than 50 μg/g would make the test population more suitable for comparison. The only differences we found are in specificity, but there are definitely also differences in sensitivity between the assays.
In conclusion, we demonstrated good analytical performance of all assays tested. Variation in the faecal calprotectin concentrations between the different methods does not allow to use these assays interchangeably. Diagnostic performance is high but depends on the clinical setting in which the test is used. Use of LRs for different result intervals aids in the clinical interpretation of faecal calprotectin results, thereby improving the clinical interpretation for the diagnosis of IBD as compared with conventional dichotomous test interpretation.
